摘要
目的:了解我院ADR的发生情况,建立与患者用药安全相关的处方管控机制,为患者合理、安全用药提供参考。方法:通过医院信息系统(HIS)收集我院2009-2010年发生的ADR报告297例,分别从年龄与性别构成、ADR严重程度、Naranjo score评分、处理方式、药品种类、ADR累及的器官或系统等进行分析。结果:257例可评估的ADR报告中,男、女比例为0.71:1,其中31～40岁患者发生ADR比例较高,占22.96%。对ADR进行Naranjo score评分,其中1～4分为可能,占88.33%;其次为5～8分为极有可能,占10.51%。对ADR进行严重成度划分,其中轻度占97.67%,中度占2.33%。ADR以药师上报居多,占56.42%。抗菌药物引发ADR位居我院首位,占27.24%;其次引发ADR较多的为诊断试剂,占18.68%。ADR主要累及皮肤及其附件,有124例(占48.25%),其次为消化系统和中枢神经系统。我院HIS中不仅将评估过的ADR反馈给上报人员并将其记载于患者的病历首页。结论:我院ADR通过自动警示预防系统在再次开处方时可起到警示作用,不但保障了患者安全、合理、有效的用药,且避免了ADR的再次发生。
OBJECTIVE： To investigate the occurrence of ADRs in our hospital and establish drug use safety-related prescrip- tion control mechanism, and to provide reference for reasonable and safe drug use. METHODS： 297 ADR reports were collected from our hospital during 2009--2010 by HIS system. The reports were analyzed in respect of patients＇ age and gender, severity of ADR, Naranjo scores, processing methods, drug types, organs or systems involved in ADR, etc. RESULTS： Of total 257 ADR cases, ratio of male and female was 0.71：1, and most of ADRs occurred in 31 -40 years old group, accountting for 22.96 %. Nara- njo score of ADR for these patients included 1-4 point which meant ADR possibly occurred （88.33%）, followed by 5-8 point which meant ADR highly probably occurred （10.51%）. The severity of ADRs ranged from mild to moderate, with 97.67% and 2.33% respectively. Major ADRs were reported by pharmacists, accounting for 56.42%. Antibiotic agents were the first reason for ADR in our hospital, accounting for 27.24%, followed by diagnostic reagents （18.68%）. Main clinical manifestations were lesion of skin and appendants, which were 124 cases （48.25%）, followed by digestive and central nervous system injury. HIS not only in- formed reporter ADRs evaluation feedback, but also recorded it in the front page of patient＇s medical records. CONCLUSION： The automatic warning and preventing system for ADR monitoring of our hospital plays warning effect on prescription in next time. It not only guarantees patient safe, reasonable and effective drug use, but also avoids reoccurrence of ADR.
出处
《中国药房》
CAS
CSCD
2012年第42期3999-4002,共4页
China Pharmacy
